Curcuminoids supplementation ameliorates iron overload, oxidative stress, hypercoagulability, and inflammation in non-transfusion-dependent β-thalassemia/Hb E patients

被引:6
|
作者
Hatairaktham, Suneerat [1 ]
Masaratana, Patarabutr [1 ]
Hantaweepant, Chattree [2 ]
Srisawat, Chatchawan [1 ]
Sirivatanauksorn, Vorapan [1 ]
Siritanaratkul, Noppadol [2 ]
Panichkul, Narumol [1 ]
Kalpravidh, Ruchaneekorn W. [1 ]
机构
[1] Mahidol Univ, Fac Med, Dept Biochem, Siriraj Hosp, 2 Wanglang Rd, Bangkok 10700, Thailand
[2] Mahidol Univ, Fac Med, Div Hematol, Dept Med,Siriraj Hosp, Bangkok, Thailand
关键词
Curcumin; Curcuminoids; Inflammation; Iron overload; Oxidative stress; Thalassemia; TRANSFERRIN-BOUND IRON; PEPTIDE HEPCIDIN; MAJOR PATIENTS; DEFERIPRONE; CYTOKINES; BENEFITS; REMOVAL; GENE;
D O I
10.1007/s00277-020-04379-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Curcuminoids, polyphenol compounds in turmeric, possess several pharmacological properties including antioxidant, iron-chelating, and anti-inflammatory activities. Effects of curcuminoids in thalassemia patients have been explored in a limited number of studies using different doses of curcuminoids. The present study aims to evaluate the effects of 24-week curcuminoids supplementation at the dosage of 500 and 1000 mg/day on iron overload, oxidative stress, hypercoagulability, and inflammation in non-transfused beta-thalassemia/Hb E patients. In general, both curcuminoids dosages significantly lowered the levels of oxidative stress, hypercoagulability, and inflammatory markers in the patients. In contrast, reductions in iron parameter levels were more remarkable in the 1000 mg/day group. Subgroup analysis revealed that a marker of hypercoagulability was significantly decreased only in patients with baseline ferritin <= 1000 ng/ml independently of curcuminoids dosage. Moreover, the alleviation of iron loading parameters was more remarkable in patients with baseline ferritin > 1000 ng/ml who receive 1000 mg/day curcuminoids. On the other hand, the responses of oxidative stress markers were higher with 500 mg/day curcuminoids regardless of baseline ferritin levels. Our study suggests that baseline ferritin levels should be considered in the supplementation of curcuminoids and the appropriate curcuminoids dosage might differ according to the required therapeutic effect. Thai Clinical Trials Registry (TCTR): TCTR20200731003; July 31, 2020 "retrospectively registered"
引用
收藏
页码:891 / 901
页数:11
相关论文
共 50 条
  • [21] Magnitude of Bone Disease in Transfusion-Dependent and Non-Transfusion-Dependent β-Thalassemia Patients
    Shamoon, Rawand P.
    Yassin, Ahmed K.
    Omar, Negar
    Saeed, Muhammad D.
    Akram, Reving
    Othman, Naska N.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (03)
  • [22] Association of iron overload with oxidative stress, hepatic damage and dyslipidemia in transfusion-dependent β-thalassemia/HbE patients
    Sengsuk C.
    Tangvarasittichai O.
    Chantanaskulwong P.
    Pimanprom A.
    Wantaneeyawong S.
    Choowet A.
    Tangvarasittichai S.
    Indian Journal of Clinical Biochemistry, 2014, 29 (3) : 298 - 305
  • [23] Deferasirox: A Review of Its Use for Chronic Iron Overload in Patients with Non-Transfusion-Dependent Thalassaemia
    Matt Shirley
    Greg L. Plosker
    Drugs, 2014, 74 : 1017 - 1027
  • [24] Deferasirox: A Review of Its Use for Chronic Iron Overload in Patients with Non-Transfusion-Dependent Thalassaemia
    Shirley, Matt
    Plosker, Greg L.
    DRUGS, 2014, 74 (09) : 1017 - 1027
  • [25] Oxidative Stress Damage of Iron Overload on Bone Marrow Erythropoiesis, Heart and Liver in Non-Transfusion Dependent Thalassemia
    Pan, Lin
    Xie, Yanni
    Yin, Xianqing
    Huang, Yumei
    Yang, Gaohui
    Li, Chan
    Chen, Yongyu
    Liu, Fengling
    Zhang, Ning
    Liang, Xiao
    Gan, Zhaoping
    Wei, Zhenbin
    Liang, Haiyan
    Liu, Qifa
    Lai, Yongrong
    Liu, Rongrong
    BLOOD, 2023, 142
  • [26] Profile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromes
    Ricchi, Paolo
    Marsella, Maria
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 6475 - 6482
  • [27] Effect of Iron Chelation Therapy on Glucose Metabolism in Non-Transfusion-Dependent Thalassemia
    Chuansumrit, Ampaiwan
    Pengpis, Pimprae
    Mahachoklertwattana, Pat
    Sirachainan, Nongnuch
    Poomthavorn, Preamrudee
    Sungkarat, Witaya
    Kadegasem, Praguywan
    Khlairit, Patcharin
    Wongwerawattanakoon, Pakawan
    BLOOD, 2015, 126 (23)
  • [28] EFFECT OF ZINC SUPPLEMENTATION ON GLUCOSE METABOLISM, OXIDATIVE STRESS AND IRON TRAFFICKING PROTEINS IN TRANSFUSION DEPENDENT PATIENTS WITH THALASSEMIA
    Walter, P.
    Curtis, C.
    Hodge, M.
    Razavi, M.
    Minkley, M.
    Lal, A.
    Higa, A.
    Killilea, D.
    Pearson, T.
    Fung, E.
    HAEMATOLOGICA, 2016, 101 : 616 - 616
  • [29] Impact of genotype on multi-organ iron and complications in patients with non-transfusion-dependent β-thalassemia intermedia
    Meloni, Antonella
    Pistoia, Laura
    Ricchi, Paolo
    Bagnato, Sergio
    Longo, Filomena
    Messina, Giuseppe
    Bagnato, Sabrina
    Rossi, Vincenza
    Renne, Stefania
    Righi, Riccardo
    Fina, Priscilla
    Positano, Vincenzo
    Cademartiri, Filippo
    ANNALS OF HEMATOLOGY, 2024, 103 (06) : 1887 - 1896
  • [30] Impact of genotype on multi-organ iron and complications in patients with non-transfusion-dependent β-thalassemia intermedia
    Antonella Meloni
    Laura Pistoia
    Paolo Ricchi
    Sergio Bagnato
    Filomena Longo
    Giuseppe Messina
    Sabrina Bagnato
    Vincenza Rossi
    Stefania Renne
    Riccardo Righi
    Priscilla Fina
    Vincenzo Positano
    Filippo Cademartiri
    Annals of Hematology, 2024, 103 : 1887 - 1896